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Proton magnetic resonance spectroscopy (1H-MRS) is largely exploited in clinical settings to non-
invasively investigate chemical compounds in human tissues. Applications of 1H-MRS in oncology field
are connected to the detection of abnormal levels of choline compounds in more active tumours,
providing useful information for cancer diagnosis and treatment monitoring. Since benign lesions may
also show presence of a choline peak, implementing absolute evaluation will help differentiating benign
from malignant tumours. An external reference procedure was described to provide choline quantifi-
cation in standard unit of measurements. Spectra were acquired on a 1.5 T scanner using both phantoms
and healthy volunteers with a PRESS sequence. The implemented quantification procedure used
metabolite and noise measurements on the spectrum to remove large part of scanner settings contrib-
uting to metabolites of interest. A standard quantification was also used to compare performances
of the noise-based method. In vitro quantification had accuracy and precision in the range (95e99)% and
(5e13)%, respectively. When applied to in vivo studies on healthy volunteers, the method provided very
close values of choline concentration, more exactly (1.73  0.24) mmol/l. The method proposed can
quantify the proper choline content in phantoms as well as in human structures, as brain. The method is
ease of use, computational costless and it can be rapidly calibrated and implemented in any centre.
 2012 Associazione Italiana di Fisica Medica. Published by Elsevier Ltd. All rights reserved.Introduction
In vivo localized proton single-voxel magnetic resonance spec-
troscopy (1H-MRS) is an application of magnetic resonance that
non-invasively provides chemical information about metabolite
content in human tissues [1]. The first clinical usage of 1H-MRS
came in the 1980s and since then 1H-MRS has become an important
application in oncology to study patients with brain cancer [2].
Recently, 1H-MRS acquisitions have been expanded to cancer
investigation in other regions of the body including prostate [3e7],
breast [1,8e12] and musculoskeletal lesions [13e15]. The potential
value of 1H-MRS in oncology is usually connected to the detection
of abnormal levels of choline compounds, typically found in more
active tumour masses [16,17]. Such molecular information is ex-
pected to be useful for cancer diagnosis, treatment monitoring and
patient follow up.
However, some recent studies demonstrated that choline
signals could also be detected in benign lesions and in normaltti).
Italiana di Fisica Medica. Publishedtissues [10,12]. For this reason a quantitative assessment is required
to accurately establish choline levels and, thus, distinguish between
the different pathologies.
Absolute determination of metabolite concentrations by
1H-MRS has been attempted by either internal or external standard
references and using known concentrations [18]. The ratio of the
area under a metabolite peak to the area of internal reference is
commonly used as a surrogate of metabolite concentration since it
is very easy to compute [19e22]. Absolute quantification (AQ) by
external reference offers some advantages: higher reproducibility
of results can be achieved, concentrations can be expressed in mM
units, internal reference, such as water or creatine (for brain
tumour masses), becomes unnecessary and tracking metabolite
variations would be more representative of actual clinical modifi-
cations during longitudinal studies. The drawbacks of external
reference AQ include time consuming data acquisition (i.e. phan-
tom calibrations) and more extensive data analysis [23].
This work describes an external reference quantification pro-
cedure to account for scanner contribution to the signal in order to
evaluate choline concentrations in human tissues. The method is
based on the observation that scanner settings simultaneously
influence signals generated bymetabolites as well as thermal noise.by Elsevier Ltd. All rights reserved.
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nical settings, can be obtained using the ratio between the
metabolite signal and spectrum noise content.
Materials and methods
Acquisition protocol
Phantom studies and in vivo measurements were performed on
a clinical whole-body scanner (Signa HDx, GE Medical System,
Milwaukee) operating at 1.5 T with standard 1H-MRS acquisition
software provided by the manufacturer. A body coil was used for
signal transmission and a dedicated eight channel high resolution
head coil (8HRBRAIN, MRI Device Corporation, Wisconsin) as a
receiver for both MR imaging and 1H-MRS. A series of T2-weighted
fast gradient echo (FGRE) images were acquired in the three spatial
planes to correctly place the spectroscopic voxel. Spectra were
collectedwith a point-resolved spectroscopy sequence (PRESS) [24]
using the following acquisition parameters: repetition time (TR)
1500 ms, echo time (TE) 35 ms [25], NEX ¼ 8, total number of
scans ¼ 128, spectral width ¼ 2500 Hz, sampling points ¼ 2048.
A short TR was selected to maintain scan duration unchanged
for both phantom studies and in vivo acquisitions. In fact, increasing
scan time in clinical settings would decrease patient compliance,
resulting in motion artifacts and would reduce overall patient
throughput. Furthermore, a longer TR would reduce the total
number of acquisitions, yielding a lower signal to noise ratio (SNR).
Automatic shimming on the unsuppressed water signal ensured
that full width at half maximum (FWHM) was equal to or less than
5 Hz. If this conditionwas not met automatically, manual shimming
was performed to adjust the FWHM to a lower value. Total imaging
time, including pre-imaging shimming adjustments and water
suppression, was less than 5 min.
Phantoms
In vitrometabolite quantification was carried out on a phantom
provided by the scanner manufacturer and on several home-built
phantoms. The first was a sphere filled with an aqueous solution
of biochemicals typically present in brain tissue. The home-built
phantoms were two sets of vials: the first was designed as a
training set for the AQ of choline and consisted of five Falcon tubes
(each one with a volume of 50 ml), filled with a choline chloride
(SigmaeAldrich, Steinheim, Germany) and bi-distillate water
solution with concentrations ranging between 0.5 and 4 mmol/l.
The second, referred to as a validation set, consisted of six vials in
which choline concentrations were different with respect to the
first set and ranged between 0.75 and 2.25 mmol/l. All of the
aqueous solutions of choline chloride were prepared in tubes of
10 cm in length and 3 cm in diameter at room temperature.
During acquisitions each sample was kept in a water container
to optimize field homogeneity, reducing magnetic susceptibility
differences at vialeair interfaces. Coil resistive load was increased
to simulate body presence by posing a 15  15  40 cm3 box filled
with NaCl and CuSO45H2O solution beside the choline-containing
Falcon tube, so that measurements were more representative of
in vivo studies.
In vitro measurements
A pre-scan procedure was run before each acquisition to define
optimal settings for analogue/digital receiver gains, transmitter
gains and water centre frequency. In fact, radiofrequency excitation
caused sample temperature rising and consequent metabolite fre-
quency shifts which, if neglected, might have produced errorsduring spectra acquisitions. If the pre-scan process had been
omitted, the default frequency as set by the scanner for excitation
would not have been optimal for the prescribed scan, thus the
metabolite content in the examined voxel would not have been
correctly stimulated. Before using the phantoms for calibration, the
influence of several scanning factors on signal amplitude was
investigated: a large quantity of spectra were acquired on the
manufacturer’s phantom to evaluate signal variations correlated to
analogue gain (G1), digital gain (G2) and voxel size (V). Measure-
ments were taken by changing one parameter at a time and holding
the others at a constant value. For example, maintaining fixed gain
values (G1 and G2) while changing voxel size ensured that all signal
variations were ascribable to the different voxel sizes.
Data processing
At the end of the acquisition process, raw data were transferred
from the scanner to a dedicatedworkstationwhere post-processing
took place. Spectra analysis was performed by homemade tools and
the reconstruction process consisted of the following steps: phase
correction, apodization, zero-filling, Fourier transform and baseline
correction. In particular, the parameter to implement zero order
phase (4) correction was obtained by Bolan’s approach [12]. Phase
was measured and corrected using the average of two different
autophasing methods: 1) the phase of the first 100 time domain
points was fitted to a straight line to obtain 4 at time t ¼ 0 and 2) 4
was chosen to maximize the smallest value of the real part of the
spectrum. A robust estimate of 4was produced using the average of
4 found when applying these two methods.
Apodization was carried out using a 1.5 Hz line broadening
decaying exponential function, while zero-filling procedure
doubled points in the spectrum, increasing the frequency point
number. Following these preliminary corrections, water sup-
pressed/unsuppressed FIDs were Fourier transformed and the
resulting spectra were frequency referenced by setting the
maximumwater peak to 4.7 ppm. The procedure was applied to all
FIDs acquired by each individual head coil channel.
The final spectrumwas constructed from the eight components,
each weighted by its SNR [8]. Water peak linewidth was used as the
parameter to accept or reject a spectrum before post-processing
steps; in this study the water peak linewidth threshold was set to
3 Hz and this value was meant only for in vitro studies. Baseline
correctionwas finally applied to the resulting spectrum as shown in
Heuer’s work [26]: to decide whether the i-th point lay on baseline,
a rectangular 15 spectral points width window was centred on it.
Maximum and minimum values within this window were extrac-
ted in order to compare their difference to noise standard deviation.
The i-th point was classified as baseline if the absolute difference
between minimum and maximum values did not exceed twice the
noise standard deviation. The final baseline was constructed by
spectrum fragments connected with straight lines.
The following analysis was implemented to automatically detect
the choline peak and to measure its area. Detection algorithm was
based on the analysis of first and second spectrum derivatives. The
first derivative was computed in the range (1, 4.5) ppm; then the
first derivative zero crossing points were determined and, where
each zero crossing point was found, the second derivative magni-
tude was compared to a threshold value to avoid spurious peak
detection. Peaks found in this step were compared to an adaptive
value, i.e. if the peak to noise ratio was greater than three, then the
algorithm returned the value in ppmwhere the peak was detected.
Once identified, it was fitted to a Gaussian bell using nonlinear
least-square regression. The fitting procedure was included in the
post-processing step to remove possible spurious signals super-
imposed on choline tails. Once the fitting procedure was
S. Mazzetti et al. / Physica Medica 29 (2013) 677e683 679completed, the peak area (Araw) was measured. This was the
starting point for the quantification procedure.
AQ procedure
A quantification method was implemented in this work to offset
deep and time consuming parameterizations of MR scanners,
typical of conventional methods. The rationale of the procedure
was based on considerations regarding acquisitions on the sphere
manufacturer phantom and the evaluation of signal variations
correlated to scanner parameters. In fact, scanner settings
(analogue and digital gains) affect both signals generated by me-
tabolites as well as signals due to thermal noise [27,28], as depicted
in Fig. 1. The ratio between the area beneath choline peak to the
area of a selected spectral region far from the metabolites present
in the specimen is not influenced by the scanner settings, thus
making it possible to obtain a choline area due principally to the
actual concentration of metabolite. As sketched in Fig. 2, noise was
measured in the flat baseline region (>8 ppm) of each spectrum,
where no metabolites were present [29,30]. The noise integration
interval to compute its area was set to 100 Hz, in order to acquire a
representative number of points describing noise spectrum con-






where Araw is the raw areameasured under the peak of cholinewith
no corrections for scanner settings, Anoise is the area under noise
spectrum and ACho is the desired area attributable to choline con-
centration with no scanner setting dependence. To define noise
integration interval we computed the mean area under the flat
region of the spectrum where no metabolites could be detected.
Mean area under noise was defined as the area under the noise
divided by the number of points belonging to the integration
interval or, equivalently, the interval length in Hz (or ppm) units.
The mean area computed under noise reached a constant value in a
100 Hz interval, and was no longer affected by strong oscillations
characterizing the very first points of this function.
Furthermore, ACho should still be corrected for longitudinal and
transversal magnetization relaxation phenomena and tempera-
ture; nevertheless, in neglecting these corrections the procedure
would systematically underestimate the ACho measurement. In case
of in vitro experiments, such systematic errors vanished whenFigure 1. Noise and choline peak areas at different G2 settings. Results are compared
with a scanner model describing the theoretical signal variation with gain. The noise-
based quantification method removes signal variation due to scanner settings since
noise and choline areas have similar behaviour when technical parameters change.in vitro area Araw was converted to mM concentration units. In case
of in vivomeasurements, such correctionwas still neglected in view
of various results available in literature [31,32].
The quantity ACho was still a surrogate of choline levels; in fact, a
calibration factor was needed in order to change ACho to [Cho]. The
calibration factor was obtained by exploiting the connection
between ACho and well-known contents of choline of the training
dataset phantoms and acquiring each available concentration at
different voxel sizes (5.8, 3.4, 1.7 and 0.7 cm3). Each experimental
point was obtained as the mean value calculated on three consec-
utive acquisitions. Using the mean calibration curve computed on
the 4 lines shown in Fig. 3, a calibration curve emergedwhose slope
was (4.23  0.14) l/mmol with R2 ¼ 0.98.
Then for each concentration belonging to the validation set, 3
measurements were performed for each voxel size to compute the
mean concentration (m) and the corresponding standard deviation
(s).
The results of this new methodology were compared with a
standard quantification method using the conventional phantom
replacement technique [18,33].Statistical analysis
The capability of the proposed procedure to finely
quantify correct choline concentration was validated on a second
set of vials. Accuracy (Equation (2)) and precision (Equation (3)) of
the method were reported as parameters that summarize the











where measured, expected and SDmeasured stand for average, true
and standard deviation values of several measurements performed
on any individual vial, respectively.
Stability of the scanner and measurement reproducibility were
verified on a phantom experimental setup. Reproducibility refers to
the precision of the measurement and the ability to repeat and
reproduce the experiment [33]. In this study, reproducibility is
interpreted as measurements with phantom repositioning and
reshimming. In the sphere phantom twenty-seven measurements
were taken in the same voxel (volume ¼ 18  18  18 mm3) with
repositioning and reshimming procedure. The voxel was placed in
the centre of the phantom and external temperature was verified
regularly from the temperature strip indicator on the phantom.In vivo quantification
At the end of this study the quantification procedure was
applied to in vivo acquisitions. Measurements were performed on
20 healthy volunteers (9 men and 11 women), between 19 and 50
years of age (mean  std ¼ 29.35  7.41 years). The volume of in-
terest was isotropic, with a side length of 20 mm and it was placed
in parietal white matter for all subjects. Particular care was taken to
optimize magnetic field homogeneity and water suppression by
localized adjustments. The same acquisition sequence was set for
in vitro and in vivo experiments and total scan time was approxi-
mately 5 min per subject.
Data acquired on healthy volunteers were elaborated according
to the scheme described for in vitro studies. Such measurements
were aimed at assessing choline distribution in brain tissues of
Figure 2. Example of in vivo acquisition showing the complete frequency range in ppm with metabolites and noisy region. The small window depicts the spectrum zoom in the
range (1.8e3.4) ppm with main brain metabolites. The model fit for the choline peak is shown above the spectrum and residuals are shown underneath.
S. Mazzetti et al. / Physica Medica 29 (2013) 677e683680selected subjects. The results were then compared to published
data available in literature [22,31,32,34].Results
In vitro study
Table 1 shows validation set choline concentrations obtained by
exploiting the noise-based method and a standard quantification
procedure. Agreement between concentrations measured by the
described procedure and the choline actually present in
samples was evaluated: accuracy and precisionwere in the range of
(95e99)% and (5e13)%, respectively.
As regards measurement reproducibility, a little variability was
found during this study. The standard method showed the worstFigure 3. Example of several calibration curves obtained from the training set at
different voxel sizes. It is important to note how experimental points disperse at a
constant choline concentration when different volumes of analysis are investigated.
The four lines are basically superimposed, meaning that no difference can be observed
in the ratio Araw/Anoise if voxel size is changed. The dotted line represents the inter-
polation of the mean curve obtained from the four experimental lines reported.performances; in fact, differences between reference and estimated
values were up to 17.0%; on the contrary, themethod here proposed
demonstrated more stable performances; maximum variation was
5.2%.
In vivo study
Table 2 and Fig. 4 summarize in vivo quantification results car-
ried out on 20 healthy volunteers. The method proposed measured
the same amount of choline as a standard quantification procedure
did in brain parietal white matter, but distribution of the results
differed according to patient variability.
Discussion
Amongmolecular imaging techniques, 1H-MRS had gained large
success as a viable tool to analyse metabolite content in tissues,
opening a new way to characterize lesions detected by conven-
tional MRI studies [35]. One advantage of 1H-MRS is its ability to
measure the concentration of biochemicals in regions of interest.
AQ is usually performed by dedicated software to process
spectroscopic data and to extract absolute concentrations of
metabolites. Two of these are particularly worth mentioning, theTable 1
Validation measurements on concentrations belonging to the validation set to test
goodness of quantification. Results obtained with a standard method of quantifi-




(m  s) mmol/l
Standard method
(m  s) mmol/l
2.25 2.29  0.07 2.28  0.07
2.00 1.99  0.25 2.09  0.19
1.75 1.82  0.14 1.72  0.12
1.25 1.23  0.08 1.22  0.07
1.00 0.94  0.13 0.91  0.13
0.75 0.73  0.07 0.76  0.06
Table 2
In vivo measurements of brain choline content in parietal white matter for 20
healthy volunteers. Choline levels were measured using the noise-based procedure





(m  s) (1.73  0.24) (1.73  0.20)
Confidence interval (95%) (1.63e1.84) (1.65e1.82)
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analysis typically measures the area beneath a metabolite peak,
then by a proper calibration factor this area can be converted into
concentration units. Two main procedures allow for calibration
which use an internal or external reference.
Using internal reference, chosen by a large number of research
groups [17], has several advantages with respect to using external
reference; in fact, separate calibration experiments as well as par-
tial volume corrections are unnecessary. However, such a proce-
dure may increase acquisition time to allow for water T1, T2 and
proton density measuring [1,37,38].
When AQ is meant to monitor treatment efficacy, it is necessary
to have a very stable reference to ascribe observed metabolite
concentration changes to a baseline to highlight the concrete
metabolite behaviour, while maintaining reproducibility of voxel
localization in the same region of analysis.
This work describes a method for AQ of choline levels by
1H-MRS studies. It uses an external reference to convert the area
beneath choline peak to metabolite concentration. The choice of an
external reference was made in light of studies which demon-
strated that internal reference concentration might vary [17,39],
contrary to the assumption that their concentrations did not
change when pathological conditions changed [1]. Methods based
on external references may normally suffer from the partial volume
effect, thus requiring correction strategies to account for it.
Nevertheless, in this study this potential improvement was not
considered because there is absolutely no compartmentation in
vials or in the manufacturer phantom. When considering healthy
volunteers, we chose homogeneous regions greater than 3.5 cc in
volume to get appropriate SNR in the spectrum. In any case, a
correction for partial volume is still possible when the procedure is
translated to in vivo studies, in the case of a mixture of different
tissue types within a given voxel [40].
Furthermore, temperature effects on signal intensity should be
considered when performing in vivo quantification. As noted by
Reyngoudt et al. neglecting temperature would result inw5% error
in concentrations [33].Figure 4. Results of the two implemented methods for quantification of brain choline
levels in 20 healthy volunteers. Dotted lines represent the interval (m  s) for each
dataset.With different relaxation times between metabolites and
reference compound, the acquired signal intensity of each reso-
nance must also be corrected [41]. This can be achieved using
correction factors, but they require knowledge of T1 and T2 relax-
ation times in tissues. When performing acquisitions at short echo
times, T2 effects cause small corrections, about 3%, that can be
ignored to avoid time consuming determination of T2 values
[42,43]. Evaluation of T1 relaxation times is often impractical in a
clinical setting, due to the excessive examination time needed to
measure it and its minor contribution to data quantification [42].
However, the correction is still possible when the operator can
estimate T1 relaxation times.
The procedure developed in this study was employed to detect
and measure choline levels in human tissues, but its main applica-
tion is actually the study and evaluation of tumour masses. In vivo
1H-MRS can detect a resonance at 3.2 ppm, containing contributions
from several different compounds, primarily glycerophosphocho-
line, phosphocholine and choline, including other metabolites such
as glycerophosphoethanolamine, phosphoethanolamine, betaine,
myo-inositol and taurine [41,44]. At lower field strengths used for
in vivowork (1.5e4 T), this complex mixture of heavily overlapping
resonances cannot be spectrally resolved and, thus, appears as a
singlepeak, termed total choline (tCho) [12]. The levels ofmetabolite
measured in vivo are then overestimated, but only slightly as choline
signal intensity corresponds to 9 protons (N(CH3)3 resonance),
whereas the signal intensity of all the other compounds corresponds
to 1 or 2 protons (CH or CH2 group), except for betainewhose signal
also corresponds to 9 protons.
Elevated choline levels are normally observed in neoplastic
tissues, thus, more accurate diagnosis would be possible if choline
levels are measured in such tissues [45,46]. The development of a
simple calibration procedure like the one used in this study can
facilitate the implementation of AQ in clinical routine. Initially, it
was thought that the procedure describing signal changes related
to scanner settings, voxel size and physical phenomena was the
best way to make choline quantification independent of MR scan-
ners. However, empirical measurements have indicated that the
method here developed can ensure precision and accuracy indices
very close to those attainable with standard and more complicated
AQ techniques, while greatly simplifying execution.
In addition, reproducibility tests reveal that the quantification
procedure was less sensitive than a conventional method to scan-
ner drifts, hardware and software upgrades. In fact, the scanner
underwent several software improvements and hardware checks
regularly throughout this study. Nevertheless, accuracy was found
to be highly stable with respect to these adjustments because noise
as well as metabolite signals have similar perturbations soon after
periodic routine inspection and scanner maintenance. According to
Equation (1), perturbations appear simultaneously at the numer-
ator and denominator, thus mutually compensating their effects.
The method’s ease of calibration is another strong point: it is
possible to calibrate the procedure using a unique vial filled with a
well-known concentration of metabolite. Implementation of the
AQ technique in other facilities is simpler than methods which
require a full recalibration process like the LCModel [36]. Further-
more, the procedure developed maintained acquisition times un-
changed with respect to usual clinical settings: all parameters
needed for quantification purposes were obtained from traditional
spectroscopic sequences without increasing acquisition times.
Translation of the method described in this work to
in vivo studies looks promising. In fact, choline levels in parietal
white matter measured by AQ were quite close to the results
obtained in similar studies by Michaelis and Pouwelset [31,32].
Both these authors carried out measurements on the same brain
region we chose and they found that choline concentration was
S. Mazzetti et al. / Physica Medica 29 (2013) 677e683682(1.8 0.3) mmol/l and (1.68 0.27) mmol/l, respectively. In fact, we
chose to cite these two authors because the relative error they
achievedwas highly compatible with the one obtained in this work.
Other studies showed even worse relative errors [22,34].
The current methodology can be extended to the quantification
of other metabolites in brain and other organs, but care must be
paid to calibrate areas by means of an appropriate phantom.
Heinzer-Schweizer et al. [47] have recently demonstrated that the
ERETIC technique is a convenient method for accurate and repro-
ducible absolute quantification (in mmol/l) of in vivometabolites in
humans. They used a synthesized RF pulse to produce an additional
peak in NMR spectrum and, after calibration of the electronic
signal, the method allowed signal quantification of all metabolites.
However, its successful application depends on the use of a
homogeneous volume coil and B1 mapping and correction. In
addition, the ERETIC method is susceptible to errors in power
optimization.
Since both spectral and spatial resolutions are linearly related to
the strength of the applied magnetic field, the use of scanners
operating at higher magnetic field strengths (3 T or higher) would
be valuable to achieve better quantification results [48]. Comparing
the results between 1.5 T and 3 T scanners, Kim et al. [49] found a
55% SNR improvement at short TE but only a 4% SNR improvement
at intermediate TE; Barker et al. [50] used an STEAM sequence to
evaluate spectroscopy results in human brain tumours and found a
28% SNR improvement at short TE when acquisitionwas performed
on 3 T magnetic field instead of 1.5 T.Conclusions
In this study metabolite concentrations in parietal white matter
of twenty health volunteers were measured by a point-resolved
1H-MRS sequence. AQ was achieved by calibration of spectral
evaluations with data from metabolite model solutions measured
under identical experimental conditions. The aim was to imple-
ment a procedure to correct acquisitions from scanner settings
contribution in order to have a spectrum independent of acquisi-
tion parameters (gains and volume of interest).
In conclusion, in vivo choline concentrations were in good
agreement with those determined by other methods in literature.
The proposed method is simple and can readily be applied in any
MR centre without the need for complicated corrections or time
consuming calibration procedures.References
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